Proteome Sciences PLC Notice of Results and Investor Presentation
April 04 2025 - 8:00AM
RNS Regulatory News
RNS Number : 7545D
Proteome Sciences PLC
04 April 2025
4 April 2025
Proteome Sciences plc
("Proteome Sciences" or the
"Company")
Notice of Results and Investor
Presentation
Proteome Sciences (AIM: PRM) announces that the
Company's results for the year ending 31 December 2024 will be
announced on 10 April 2025 (the "Final Results"). The Company looks
forward to updating shareholders on the Company's performance and
on the outlook for 2025.
On the 11 April 2025 at 10:30 BST the Company's
Executive Chairman, Christopher Pearce and Dr Ian Pike, the Chief
Scientific Officer (CSO), will provide a live presentation relating
to the Final Results via Investor Meet Company.
The presentation is open to all existing and
potential shareholders. Questions can be submitted pre-event via
your Investor Meet Company dashboard up until 10 April 2025, 09:00
BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company
for free and add to meet Proteome Sciences via:
https://www.investormeetcompany.com/proteome-sciences-plc/register-investor
Investors who already follow Proteome Sciences
on the Investor Meet Company platform will automatically be
invited.
For further
information please contact:
|
Proteome Sciences plc
|
|
Dr. Ian Pike, Chief Scientific
Officer
|
Tel: +44 (0)20 7043 2116
|
|
|
Richard Dennis, Chief Commercial
Officer
|
|
|
|
Allenby Capital Limited (Nominated Adviser &
Broker)
|
|
|
John Depasquale/Lauren Wright
(Corporate Finance)
Tony Quirke/Stefano Aquilino (Equity
Sales & Corporate Broking)
|
Tel: +44 (0) 20 3328 5656
|
|
|
|
|
|
|
| |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider
of contract proteomics services to enable drug discovery,
development and biomarker identification, and employs proprietary
workflows for the optimum analysis of tissues, cells and body
fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of
biological activity, while analysis using Super-Depletion and
TMTcalibrator™ provides access to over 8,500 circulating plasma
proteins for the discovery of disease-related biomarkers. Targeted
assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORIIMBTMTTMBJA
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Jun 2025 to Jul 2025
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Jul 2024 to Jul 2025
